Abstract:Background: Lung cancer is the most prevalent type of cancer and the leading cause of cancer-related death. Chemotherapic resistance is one of the most prominent obstacles to treating lung cancer patients. Skp2 is upregulated, accompanied by the downregulation of MLKL and contributes to cisplatin resistance in NSCLC. We investigated the mechanism underlying the aberrant Skp2 linked to cisplatin resistance in NSCLC. Methods: We confirmed Skp2 and MLKL interaction by co-immunoprecipitation assays. We analyzed the biologic consequences of knockdown or overexpression of Skp2 using immunoblotting, immunoprecipitation, and immunohistochemistry. We analyzed Skp2-regulated MLKL degradation by ubiquitination assays. We tested the functions of Skp2, Skp2-ubiquitinated MLKL degradation and NSCLC chemoresistance by measuring cell viability, anchorage-independent cell growth, and mouse xenograft tumorigenesis. Results: Skp2 is overexpressed, accompanied by the downregulation of MLKL in human NSCLC tissues and cell lines. Knockdown of Skp2 inhibited cell viability, colony formation, and xenograft tumor growth. We demonstrated that Skp2 interacted with MLKL and promoted the ubiquitination and degradation of MLKL in NSCLC cell lines. Notably, Skp2 was highly expressed in cisplatin-resistant NSCLC cells and negatively correlated with MLKL. Furthermore, the silence of Skp2 partially restored MLKL and sensitized NSCLC cells to cisplatin. Interpretation: Our results suggest that the inhibition of Skp2-regulated MLKL ubiquitination may overcome NSCLC chemoresistance.Funding: This work was supported by the National Natural Science Foundation of China (No. 82073260, 81972837, 82003203, 81572280, 81401548) and the Natural Science Foundation of Hunan Province (No. 2021JJ31011, 2021JJ41058).Declaration of Interest: The authors have declared no conflicts of interest.Ethical Approval: This study was approved by the Ethics Committee of the Second Xiangya Hospital or the Ethics Committee of Xiangya Hospital, Central South University, China. All the patients provided their written informed consent. The animal experiments were approved by the Medical Research Animal Ethics Committee, Central South University, China.

PDK2 induces Cisplatin-resistance in lung adenocarcinoma via transcriptional regulation of CNNM3.

HOXA4-Dependent Transcriptional Activation of AXL Promotes Cisplatin- Resistance in Lung Adenocarcinoma Cells.

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

Transcriptome analysis reveals PRKCA as a potential therapeutic target for overcoming cisplatin resistance in lung cancer through ferroptosis

Inhibition of Protein Kinase CK2 Sensitizes Non-Small Cell Lung Cancer Cells to Cisplatin Via Upregulation of PML

Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients

Transcriptome Sequencing Reveals Key Pathways And Genes Associated With Cisplatin Resistance In Lung Adenocarcinoma A549 Cells

Camptothecin And Cisplatin Upregulate Abcg2 And Mrp2 Expression By Activating The Atmunf-Kappa B Pathway In Lung Cancer Cells

Pyruvate Dehydrogenase Kinase 1 Contributes to Cisplatin Resistance of Ovarian Cancer Through EGFR Activation.

Overexpression of SMARCA2 or CAMK2D is Associated with Cisplatin Resistance in Human Epithelial Ovarian Cancer

PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma

Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells

Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2

DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines

CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC)

DCBLD2 Mediates Epithelial-Mesenchymal Transition-Induced Metastasis by Cisplatin in Lung Adenocarcinoma

Skp2-Ubiquitinated MLKL Degradation Confers Cisplatin-Resistant in NSCLC Cells

PLEK2 activates the PI3K/AKT signaling pathway to drive lung adenocarcinoma progression by upregulating SPC25

PPIP5K2 Facilitates Proliferation and Metastasis of Non-Small Lung Cancer (NSCLC) through AKT Signaling Pathway

CRISPR/Cas9 Library Screening Uncovered Methylated PKP2 As a Critical Driver of Lung Cancer Radioresistance by Stabilizing Β-Catenin.

High PKD2 predicts poor prognosis in lung adenocarcinoma via promoting Epithelial–mesenchymal Transition